Garuda Therapeutics Launches with $72 Million Series A Financing
Retrieved on:
Thursday, September 23, 2021
Biotechnology, Surgery, Health, Stem Cells, Pharmaceutical, Therapy, Harvard University, Regius Professor of Medicine, MIT, Bone marrow, Collection, Stanford University School of Medicine, Patient, Coronavirus Scientific Advisory Board (Turkey), CFA, CEO, Industry, Broad Institute, Principal, Associate, Entrepreneurship, Technology, Sickle cell disease, History, Safety, Pharmaceutical industry
Garuda is developing the worlds first, off-the-shelf hematopoietic stem cell platform that will eliminate dependency on donor or patient cells.
Key Points:
- Garuda is developing the worlds first, off-the-shelf hematopoietic stem cell platform that will eliminate dependency on donor or patient cells.
- Currently, patients seeking a blood stem cell transplant, must find a suitable human donor as a source of blood stem cells.
- Our technology has the potential to transform blood stem cell transplants, revolutionizing the landscape of medicine, said Dhvanit Shah, Ph.D., Co-Founder, President and CEO of Garuda Therapeutics.
- Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants.